The 'Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030' report provides a comprehensive study of the current market landscape of non-antibody protein scaffolds, and related drugs and diagnostics, featuring an elaborate discussion on the likely future potential of this upcoming market. Presently, there is one approved product (Kalbitor®), and several non-antibody protein scaffold based product candidates that are being developed across various clinical and preclinical stages. Although the concept of non-antibody protein scaffolds was conceived more than a decade ago, this field has gained popularity in recent years. Amongst other novel formats, non-antibody protein scaffolds have emerged as viable alternatives, having the capability to address the existing challenges associated with classical antibody based therapies.
The above-mentioned limitations have prompted researchers to identify alternative protein scaffold based therapeutic strategies. These drawbacks are related to their inherent structural complexities, high manufacturing costs, difficulties in formulation and insufficient understanding of their precise in vivo mechanisms of action. However, despite their clinical and commercial successes, these therapies are known to have certain drawbacks that have had an impact on their overall efficacy, thereby, limiting their therapeutic potential. The first product candidate was launched in 1986 since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious diseases. Monoclonal antibodies have been in use for more than two decades.
0 kommentar(er)
